Gen1e
2 known investors
GEn1E is a life sciences company developing next-generation substrate-specific p38α kinase inhibitors to treat rare and inflammatory diseases. It combines a curated database linking genes, pathways, proteins, diseases, and compounds with machine learning models spanning drug discovery through clinical trials.
Also known as GEn1E · GEn1E Lifesciences
Investors · 2
Company profile
researched Aug 2026GEn1E Lifesciences is a clinical-stage biopharmaceutical company developing first-in-class precision therapies for inflammatory and rare diseases. Its scientific focus is on dysregulation of the p38, MK2 and ERK kinase pathways, which it identifies as contributors to the pathogenesis of several inflammatory diseases. The company positions its compounds against earlier generations of kinase inhibitors, which it characterizes as immunosuppressive and associated with off-target effects, toxicity and a lack of specificity.
The pipeline comprises three key programs across two targets. GEn-1124 IV, a p38α:MK2 dual signal modulator, is in development for acute respiratory distress syndrome (ARDS) and is the company's Phase 2 asset; GEn-1124 Oral is an undisclosed ("stealth") chronic indication program, and GEn-1123 Oral is an undisclosed program for a rare chronic indication. A next-generation ERK 1/2 modulator program is also listed as stealth. The GEn-1124-002 trial is a two-part Phase 2 study evaluating the safety and tolerability of GEn-1124 in subjects with ARDS, with intravenous infusion initiated as early as possible after ARDS diagnosis, a second dose roughly eight hours later, and twice-daily dosing continued for five days. Separately, the company's dual signal modulator has received US FDA Orphan Drug and Rare Pediatric Disease designations for Duchenne muscular dystrophy.
Business model
GEn1E develops proprietary first-in-class small-molecule therapeutics in-house, advancing them from discovery through clinical development. Its GRID AI platform is described as built "by GEn1E, for GEn1E," indicating it is used internally to accelerate the company's own drug development rather than offered as a standalone product. The company lists a partners function on its website.
Traction
GEn1E reports 21 first-in-class compounds generated, one asset in Phase 2 (GEn-1124 IV for ARDS), three preclinical programs, and progression from early discovery to Phase 2 within 2.5 years on seed capital. Regulatory traction includes US FDA Orphan Drug and Rare Pediatric Disease designations for its dual signal modulator in Duchenne muscular dystrophy.
Latest developments
Recent announcements include the appointment of François Nader, MD, as Chairman of the Board of Directors and the granting by the US FDA of Orphan Drug and Rare Pediatric Disease designations to the company's dual signal modulator for Duchenne muscular dystrophy. The company also featured in a Forbes Japan article on how geopolitics is shaping AI-driven drug development.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
GEn1E presents itself as a clinical-stage, Phase 2 company pursuing first-in-class precision therapies in an area where prior kinase-inhibitor approaches have been limited by immunosuppression, toxicity and lack of specificity.
GEn1E states that traditional kinase inhibitors target the ATP binding pocket via covalent bonding, whereas its platform identified a new binding pocket that allows targeting of specific functions through allosteric binding. Its compounds are described as selective dual signal modulators rather than non-selective, immunosuppressive inhibitors, giving a differentiated mechanism of action for treating inflammation. The company says this mechanism of action has been presented at the American Thoracic Society (ATS) meetings in 2023 and 2024.
Technology
The company's GRID AI platform combines a curated database of public and proprietary data linking genes, pathways, proteins, diseases and its own compounds with machine learning models covering the process chain from drug discovery through clinical trials, intended to accelerate development. The platform is credited with identifying a new, non-ATP binding pocket enabling allosteric, substrate-specific targeting, with a focus on next-generation substrate-specific p38α kinase inhibitors.
Go-to-market
Patients with acute and chronic inflammatory and rare diseases, including acute respiratory distress syndrome and Duchenne muscular dystrophy.
Geography
The company describes itself as a Silicon Valley company.
History
The company's website carries a copyright range beginning in 2018. It states that it advanced from early discovery to Phase 2 in 2.5 years using seed capital, has generated 21 first-in-class compounds, and now has one asset in Phase 2 and three preclinical programs. Its mechanism of action work was presented at the ATS conferences in 2023 and 2024. More recently, the US FDA granted Orphan Drug and Rare Pediatric Disease designations to its dual signal modulator for Duchenne muscular dystrophy, and François Nader, MD, was appointed Chair of the Board of Directors.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsGEn1E Lifesciences announced the appointment of François Nader, MD, as Chairman of its Board of Directors.
The US FDA granted Orphan Drug and Rare Pediatric Disease designations to GEn1E Lifesciences' dual signal modulator for the treatment of Duchenne muscular dystrophy.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- Gen1egen1elifesci.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Gen1e do?
- Clinical-stage biotech developing first-in-class p38α:MK2 and ERK modulators for inflammatory and rare diseases.
- Who are Gen1e's investors?
- Gen1e's investors include Flucas Ventures, BoxOne Ventures.